| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Osimertinib | Osimertinib Impurity 2 DiHCl | VL6030013 | View |
| Osimertinib | Osimertinib Impurity 9 HCl | VL6030002 | View |
| Osimertinib | Osimertinib Impurity N | VL6030008 | View CAS 1932710-29-6 |
| Osimertinib | Osimertinib Inhouse Impurity I | VL6030004 | View |
| Osimertinib | Osimertinib N'-Oxide | VL6030007 | View |
| Catalogue No. | VL6030008 |
| CAS No. | 1932710-29-6 |
| Molecular Formula | C31H35N7O3 |
| Molecular Weight | 553.65 g/mol |
| Parent drug | Osimertinib |
| IUPAC Name | N-Acryloyl Osimertinib ; N-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)-N-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)acrylamide |
| Synonyms | N/A |
| References | Sci-Hub, Patent Review of Manufacturing Routes to Oncology Drugs: Carfilzomib, Osimertinib, and Venetoclax, 10.1021/acs.oprd.6b00374. (2016). Zidianzhan.net. https://sci-hub.zidianzhan.net/10.1021/acs.oprd.6b00374 |
| Status | In-stock |
| ListName | Osimertinib Impurity N |
| Exclusively Supplied by Veeprho | Exclusively Supplied by Veeprho |
"*" indicates required fields
